United States · Biotechnology startup
United States · AnaptysBio
AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics.
Listed
Follow AnaptysBio and see its new rounds in your feed.Start following
About AnaptysBio
AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics.
We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.
Founders and team
From AnaptysBio's own website and the SEC filings it signed: 1 founder, 7 on the team.
- Daniel FagaPresident, CEO, and Director
- Owen HughesCEO of XOMA Royalty
- Christopher MurphyCFO
- John OrwinBoard Chairman of First Tracks Bio
- Hamza SuriaExecutive Officer, Directori
- Marco LondeiExecutive Officeri
- Robert HoffmanExecutive Officeri
On the board, as filediCarol GallagherHollings RentonJames TopperJohn SchmidNicholas LydonTiba Aynechi
On 2 portfolio pages
Investors who name them
Each firm lists AnaptysBio on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put AnaptysBio in front of investors. Or tell us what we have wrong.